Africa Clean Energy Solutions Limited (MUSE:ACES.N0000)

Marinus Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Revenue	0.09	0.8	0.56	0.27	0.22	-
Revenue Growth (YoY)	-93.48%	41.75%	110.14%	19.52%	-	-
Selling, General & Admin	0.63	0.75	0.7	0.57	0.57	0.39
Provision for Bad Debts	0.01	0.01	0.04	0.01	-	-
Other Operating Expenses	-0.1	0.81	0.58	0.02	0.04	0.03
Total Operating Expenses	0.54	1.57	1.33	0.6	0.61	0.42
Operating Income	-0.45	-0.77	-0.77	-0.34	-0.38	-0.42
Interest Expense	-0.11	-0.06	-0.04	-0.01	-0.01	-0.03
Interest Income	0.05	0.05	0.05	0.19	0.18	0.06
Net Interest Expense	-0.06	-0.01	0.01	0.18	0.17	0.03
Income (Loss) on Equity Investments	-	-	-0.06	-0.31	-	-0
Currency Exchange Gain (Loss)	-0	-	-0.22	-0.27	0.42	-
Other Non-Operating Income (Expenses)	-0	-	-	-	-	-
EBT Excluding Unusual Items	-0.51	-0.79	-1.03	-0.73	0.2	-0.39
Impairment of Goodwill	-	-	-0.02	-0.13	-0.01	-0.6
Gain (Loss) on Sale of Investments	-	-	-	0.01	-	-
Gain (Loss) on Sale of Assets	-	-	-0.21	-0.02	-	0.09
Asset Writedown	-1.22	-1.22	-0.4	-	-	-
Other Unusual Items	-	-	-	-	-0.07	-
Pretax Income	-1.73	-2.01	-1.66	-0.87	0.12	-0.9
Income Tax Expense	-	-	-	0.02	-	-
Earnings From Continuing Ops.	-1.73	-2.01	-1.66	-0.89	0.12	-0.9
Minority Interest in Earnings	0.06	0.8	0.33	0.01	-0.03	0.03
Net Income	-1.67	-1.21	-1.33	-0.88	0.09	-0.87
Net Income to Common	-1.67	-1.21	-1.33	-0.88	0.09	-0.87
Shares Outstanding (Basic)	32	31	29	29	29	27
Shares Outstanding (Diluted)	32	31	29	29	29	27
Shares Change (YoY)	4.96%	5.40%	0.72%	0.05%	7.92%	8.69%
EPS (Basic)	-0.05	-0.04	-0.05	-0.03	0.00	-0.03
EPS (Diluted)	-0.05	-0.04	-0.05	-0.03	0.00	-0.03
Free Cash Flow	-0.19	-0.28	-0.31	-0.25	0.11	-0.27
Free Cash Flow Per Share	-0.01	-0.01	-0.01	-0.01	0.00	-0.01
Profit Margin	-1931.84%	-151.46%	-236.26%	-327.52%	40.83%	-
Free Cash Flow Margin	-216.95%	-35.67%	-54.62%	-95.18%	48.77%	-
EBITDA	-	-0.77	-0.76	-0.34	-0.38	-0.42
EBITDA Margin	-	-97.25%	-136.16%	-125.85%	-170.72%	-
D&A For EBITDA	-	0	0	0	0	0
EBIT	-0.45	-0.77	-0.77	-0.34	-0.38	-0.42
EBIT Margin	-	-97.31%	-136.24%	-126.10%	-171.02%	-
Revenue as Reported	0.09	0.81	0.61	0.47	0.83	0.15

Updated May 13, 2024. Source: S&P Global Market Intelligence. Utility template. Financial Sources.